NFKB1 and chronic kidney disease: In CKD, MS417 hinders the transcriptional activation of pro-inflammatory cytokines and chemokines linked to the NF-kB pathway, leading to a decrease in the expression of IL-6 and CCL2, thereby attenuating the infiltration of inflammatory cells and glomerular injury [257].